Geron Co. (NASDAQ:GERN) traded down 7.7% during mid-day trading on Friday . The stock traded as low as $1.68 and last traded at $1.69. 4,431,393 shares traded hands during trading, an increase of 34% from the average session volume of 3,303,507 shares. The stock had previously closed at $1.83.
Several equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Geron from a “hold” rating to a “buy” rating in a research report on Saturday, March 16th. ValuEngine upgraded shares of Geron from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. BTIG Research assumed coverage on shares of Geron in a research report on Tuesday, February 12th. They set a “buy” rating and a $4.00 target price for the company. Zacks Investment Research upgraded shares of Geron from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 4th. Finally, B. Riley upgraded shares of Geron from a “neutral” rating to a “buy” rating and lifted their target price for the company from $1.50 to $3.25 in a research report on Thursday, January 31st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Geron currently has a consensus rating of “Buy” and a consensus price target of $3.39.
The firm has a market capitalization of $315.00 million, a price-to-earnings ratio of -10.56 and a beta of 2.94.
Geron (NASDAQ:GERN) last announced its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.05). The firm had revenue of $0.38 million during the quarter, compared to analyst estimates of $0.22 million. Geron had a negative net margin of 2,534.43% and a negative return on equity of 17.61%. Equities analysts anticipate that Geron Co. will post -0.34 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Amalgamated Bank purchased a new position in shares of Geron in the fourth quarter worth $25,000. IHT Wealth Management LLC purchased a new position in shares of Geron in the fourth quarter worth $37,000. HRT Financial LLC increased its stake in shares of Geron by 192.6% in the fourth quarter. HRT Financial LLC now owns 40,098 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 26,393 shares during the period. SVA Plumb Wealth Management LLC increased its stake in shares of Geron by 98.8% in the fourth quarter. SVA Plumb Wealth Management LLC now owns 50,300 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 25,000 shares during the period. Finally, SG Americas Securities LLC increased its stake in shares of Geron by 99.6% in the fourth quarter. SG Americas Securities LLC now owns 56,479 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 28,181 shares during the period. Hedge funds and other institutional investors own 33.54% of the company’s stock.
Geron Company Profile (NASDAQ:GERN)
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Read More: Economic Reports
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.